Target Information

Target General Information

Top

Target ID

T10362 (Former ID: TTDI01629)

Target Name

Enzyme unspecific (Enz)

Gene Name

NO-GeName

Target Type

Successful target

[1]

Disease

[+] 2 Target-related Diseases

Female genital tract inflammatory disorder [ICD-11: GA0Z]

Human immunodeficiency virus disease [ICD-11: 1C60-1C62]

UniProt ID

NOUNIPROTAC

Drugs and Modes of Action

Top

Approved Drug(s)

[+] 2 Approved Drugs

Desoxyribonuclease

Drug Info

Approved

Female genital tract inflammation

[2]

Glutathione

Drug Info

Approved

Human immunodeficiency virus infection

[2], [3]

Clinical Trial Drug(s)

[+] 4 Clinical Trial Drugs

HTI-101

Drug Info

Phase 2

Obesity

[4]

VT-1129

Drug Info

Phase 2

Onchocerciasis

[5]

ASC-101

Drug Info

Phase 1/2

Haematological malignancy

[6]

BXCL702

Drug Info

Phase 1

Haematological malignancy

[7]

Discontinued Drug(s)

[+] 7 Discontinued Drugs

A-11259

Drug Info

Terminated

Bacterial infection

[8]

A-364

Drug Info

Terminated

Bacterial infection

[9]

APC-6336

Drug Info

Terminated

Hepatitis C virus infection

[10]

BM-13677

Drug Info

Terminated

Diabetic complication

[11]

GW-278884

Drug Info

Terminated

Colorectal cancer

[12]

NZ-1002

Drug Info

Terminated

Lysosomal storage disease

[13]

SRI-3072

Drug Info

Terminated

Mycobacterium infection

[14]

Mode of Action

[+] 3 Modes of Action

Modulator

[+] 7 Modulator drugs

Desoxyribonuclease

Drug Info

[2], [15]

Glutathione

Drug Info

[1], [2]

ASC-101

Drug Info

[18]

BM-13677

Drug Info

[22]

GW-278884

Drug Info

[23]

NZ-1002

Drug Info

[24]

A-76341

Drug Info

[25]

Antagonist

[+] 1 Antagonist drugs

HTI-101

Drug Info

[16]

Inhibitor

[+] 6 Inhibitor drugs

VT-1129

Drug Info

[17]

BXCL702

Drug Info

[7]

A-11259

Drug Info

[19]

A-364

Drug Info

[20]

APC-6336

Drug Info

[21]

SRI-3072

Drug Info

[14]

Drug Property Profile of Target

Top

(1) Molecular Weight (mw) based Drug Clustering

(2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering

(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering

(4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering

(5) Rotatable Bond Count (rotbonds) based Drug Clustering

(6) Topological Polar Surface Area (polararea) based Drug Clustering

"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five

References

Top

REF 1

Methionine and cysteine affect glutathione level, glutathione-related enzyme activities and the expression of glutathione S-transferase isozymes in rat hepatocytes. J Nutr. 1997 Nov;127(11):2135-41.

REF 2

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

REF 3

URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6737).

REF 4

Clinical pipeline report, company report or official report of Hemodynamic Therapeutics.

REF 5

ClinicalTrials.gov (NCT01891305) A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea Pedis. U.S. National Institutes of Health.

REF 6

ClinicalTrials.gov (NCT01983761) Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation. U.S. National Institutes of Health.

REF 7

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 8

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016810)

REF 9

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016809)

REF 10

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010742)

REF 11

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004142)

REF 12

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011272)

REF 13

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015179)

REF 14

2-Alkoxycarbonylaminopyridines: inhibitors of Mycobacterium tuberculosis FtsZ. J Antimicrob Chemother. 2002 Jul;50(1):111-4.

REF 15

Preparation of the bifunctional enzyme ribonuclease-deoxyribonuclease by cross-linkage. Biochemistry. 1979 Oct 2;18(20):4449-52.

REF 16

Halozyme Therapeutics Announces New Studies From HTI-101 Presented at Proteoglycan Research Conference. Halozyme Therapeutics. JULY 12, 2006.

REF 17

The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother. 2014 Dec;58(12):7121-7.

REF 18

ClinicalTrials.gov (NCT01983761) Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation. U.S. National Institutes of Health.

REF 19

The Identification of Nanomolar 1,4-benzoquinone Inhibitors of Shikimate Kinase. Aspergillus & Aspergillosis Website. 2002.

REF 20

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015550)

REF 21

CN patent application no. 103263414, Application of 2,2'-(1,4-phenylene)di(benzimidazole-5-carboxylic acid) in preparation of antitumor drug.

REF 22

Progress in medicinal chemistry, 1994. Page(448).

REF 23

WO patent application no. 2010,1112,71, Orally bioavailable lipid-based constructs.

REF 24

Expression of a cytokinin synthesis gene from Agrobacterium tumefaciens T-DNA in basket willow (Salix viminalis). Physiologia Plantarum Volume 88, Issue 3, pages 439-445, July 1993.

REF 25

WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Prof. Feng ZHU

Prof. Yuzong CHEN